Prelude Therapeutics Inc (NASDAQ: PRLD) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapies for cancer. The company generates no product revenue and funds operations through equity issuances, including a securities purchase agreement with Incyte Corporation that raised $25.0 million in gross proceeds during FY2025. Prelude operates in a competitive oncology drug development market alongside major pharmaceutical companies and specialty pharmaceutical companies, as noted in the FY2025 10-K filed March 10, 2026. As of December 31, 2025, Prelude had 79 full-time employees and leased approximately 81,000 square feet of office and lab space at its Chestnut Run facility. Net cash used in operating activities was $56.3 million in FY2025, down from $102.9 million in FY2024. The company has an exclusive option agreement with Incyte Corporation dated November 3, 2025, and relies on third-party contract organizations for clinical trial conduct and manufacturing.

Revenue model

Prelude has no product revenue as of the FY2025 10-K. Operations are funded through equity issuances, including $25.0 million in gross proceeds from a securities purchase agreement with Incyte Corporation in FY2025, and an at-the-market facility with Jefferies LLC under an Open Market Sale Agreement dated March 15, 2023.

Products and services

Prelude develops small-molecule oncology product candidates in preclinical and clinical stages. The FY2025 10-K does not name specific approved products. The company has an exclusive option agreement with Incyte Corporation dated November 3, 2025, covering unspecified product candidate rights.

Customers and end markets

No commercial customers as of December 31, 2025. End market is oncology therapeutics. The company's counterparty relationship with Incyte Corporation is the only disclosed commercial arrangement in the FY2025 filing.

Value-chain role

Drug discovery and clinical-stage development. Prelude outsources clinical trial conduct and manufacturing to third-party contract organizations. As of December 31, 2025, the company had not commercialized any product and had no internal sales or marketing infrastructure.

Geographic exposure

The FY2025 10-K does not specify geographic markets beyond U.S. operations. Principal office and lab space is at the Chestnut Run facility, approximately 81,000 square feet, with a sublease of approximately 20,000 square feet beginning December 2025.

Source: SEC 10-K, filed 2026-03-10

Industry: Pharmaceutical Preparations Peers: Aldeyra Therapeutics Inc MiMedx Group Inc Atara Biotherapeutics Inc BioXcel Therapeutics Inc Kalvista Pharmaceuticals Inc Eiger BioPharmaceuticals, Inc. Foghorn Therapeutics Inc Vigil Neuroscience, Inc. Tyra Biosciences Inc